Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.
BörsenkürzelAGMB
Name des UnternehmensAgomab Therapeutics NV
IPO-datumFeb 06, 2026
CEOKnotnerus (Tim)
Anzahl der mitarbeiter- -
WertpapierartDepository Receipt
GeschäftsjahresendeFeb 06
AddressePosthoflei 1/6
Stadt
BörseNASDAQ OMX - NASDAQ BASIC
LandBelgium
Postleitzahl2600
Telefon
Websitehttps://agomab.com/
BörsenkürzelAGMB
IPO-datumFeb 06, 2026
CEOKnotnerus (Tim)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten